Progesterone Receptors

4,7-Dihydroxycoumarin is a potent inhibitor of the epidermal growth factor receptor (EGFR) as well as estrogen and progesterone receptors. It exhibits significant cytotoxicity against breast cancer cells, with an IC50 value of 18.36 μg/mL. This compound is valuable for research focused on breast cancer treatment and the exploration of hormone receptor interactions.

Mifepristone methochloride is a selective progesterone receptor inhibitor. It functions as a glucocorticoid antagonist, effectively blocking peripheral glucocorticoid and progesterone receptors. This compound has demonstrated minimal effects on intraocular pressure in preclinical studies, making it suitable for research into ocular pharmacology. The water-soluble formulation of Mifepristone methochloride is designed to enhance drug penetration in ocular tissues, facilitating studies on its therapeutic potential in eye diseases.

CP8754 is a selective antagonist of the human progesterone receptor (hPR), acting primarily by competitively inhibiting the binding of [3H]-progesterone. This compound effectively impedes progesterone-mediated signaling, as evidenced by its ability to inhibit both exogenous luciferase and endogenous alkaline phosphatase expression in vitro, and to suppress rabbit endometrial transformation in vivo. CP8754 exhibits minimal binding affinity for human glucocorticoid receptors, estrogen receptors, and rat androgen receptors, making it a valuable tool for investigating progesterone-related diseases, including breast cancer, endometriosis, uterine fibroids, and hormone-dependent tumors.